Reshaping women's health through the understanding of gynecological fluids. WomEC: Antibody-based IVD test based on 5 novel protein biomarkers quantified in liquid biopsybroad
WomEC · Horizon Europe grant · 2023-10-01–2026-06-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →
Objective
WomEC is the future of endometrial cancer (EC) diagnosis. It is an in vitro diagnostic test for EC based on 5 novel protein biomarkers that are analyzed in the fluid of a pipelle biopsy, providing a 97% Negative Predictive Value. WomEC has been verified in 4 clinical retrospective studies in 530 patients that resulted in two patents. A verified immunoassay prototype incorporating a proprietary algorithm and antibodies will be completed by January 2023 with clinical validation and commercialization expected for 2024. WomEC is targeted at public and private hospital systems (clinical laboratories) and will benefits woman undergoing the diagnostic process by providing: a faster, more accurate diagnosis, with fewer complications by eliminating the need for invasive tests; and by providing tumor histologic information to improve clinical decision making and optimize surgical treatment leading to a better quality of life, increased life expectancy and reduced cost of care.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| MIMARK DIAGNOSTICS SL | ES | coordinator | €2,499,999 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.